The URL can be used to link to this page

Home My WebLink AboutEmailed Comments from Robert GoldbergQuestions & Comments for 4/26/21 Open Session from Robert Goldberg Item C: Demand on Treasury (Warrants Page 13, Check #19450 to Stantec Consulting for $12,892 for "Lampson Ave Drainage Improvement Project 3-3-21.". What is this project? Item E: Report of City Manager and Dept Head Authorized Contracts Contract with DxTerity for COVID-19 Testing: Per the contract posted to the City Clerk's database (key pages attached), DxTerity will provide on-site employee saliva testing and at home mail -in kits. The former costs $50 each, the latter $125 each. The warrants from the last Council meeting included #19061 for $65,050 for approximately three months of testing from November through January. It is unclear from the warrant detail how many on-site tests were done vs. home kits. However, if all of the testing performed was on-site, $65,000 would pay for testing of a 100 employees weekly for a period of 13 weeks. Please describe our employee testing program. Who is being tested and how often? Is the cost of testing reimbursable from any State or Federal program? Have we incurred an additional $65,000 in testing costs for the three months of February through April? [Note that this contract has no dollar limit] What is the plan for winding down this program? Item K: Street Lighting Assessment District The Engineer's Report (page 7) gives an estimated figure of $200,000 for utility costs. This is a 7% increase from the estimated utility cost of $186,800 in the Reports for FY 20-21, FY 19-20, and FY 18-19. The Report provides no analysis or discussion for the basis of this 7% cost increase. Of note is that utility costs in FY 21-22 should reflect the full impact of the expected $15,000/year savings generated by the recent conversion to LED's. The prior estimates of $186,800 did not factor this saving into account. In trying to understand the source of the current $200,000 estimate for utility costs, I reviewed the recently released FY 19-20 CAFR. Page 107 (attached) shows total expenditures of $199,431. However, this figure includes the annual assessment engineer's cost of $9600. 1 suspect the $200,000 estimate in current Engineer's Report derives from this CAFR figure. However, the Engineer's Report also lists the $9600 annual assessment cost as a separate additional expense, thus, appearing to double count it. Recommendation: The Engineer's estimate of utility costs should be reduced by $9600 to $190,400 to eliminate double -counting of the annual engineering assessment. This would subsequently decrease the FY21-22 General Fund contribution by $9600 as well, and free this money for other Council priorities during the upcoming budget process. DocuS:^yn Envelope •.D 250COB11-7EDA-4E7[)-!MCF•E83M26FA6F1 DxTerity DxTerity Employer Testing Agreement Between DxTerity, Inc. and The City of Seal Beach THIS AGREEMENT is entered effective as of January 12, 2021 (the "Effective Date"), between DxTerity Diagnostics, Inc., with offices located at 19500 South Rancho Way Suite 116, Rancho Dominquez, California, 94220 ("DxTerity") and The City of Seal Beach with offices located at 211 Eighth Street, Seal Beach, CA 90740 ("Company'). DxTerity and Company shall be referred to hereafter Individually as a "Party" and collectively as the "Parties" to this Agreement. Company wishes to engage DxTerity as a provider for the SafeWorkax Employer Testing Services ("Services") as defined in Exhibits A and 6, upon the terms and conditions set forth in this Agreement and DxTerity wishes to provide to Company's employees and individuals the Services upon those terms and conditions described below. The Company understands that the Services under this Agreement are offered in accordance with Emergency Use Authorizations from the EDA for COVID-19 testing and Clinical Laboratory guidelines as required. The Services are not reimbursable by any federal health care program or commercial insurance companies. The Company is responsible for all costs associated with the Services. Important limitations of the COVID-19 Employer Testing Service: I. All employees using the Services must sign a voluntary informed consent Form prior to the collection of samples for shipment to DxTerity. It is the Company's responsibility to obtain the consent. II. The Company Understands the instructions provided to company representatives must be followed both by the individual and the responsible representatives to conduct this service. III, further the Company understands: a. As with all tests, there are risks of false positives. b. As with all tests, there is a risk of false negatives. There is also a risk that some infected individuals may have some level of COVID-19 infection below the sensitivity of the testing method. c. There is an on-going risk of COVID-19 infection, so repeat testing of employees an a regular basis should be considered as appropriate. d. i his Service tests only for the presence of zhe virus that causes COVID-19 (5ARS-CoV-2). e. Company should guide employees on CDC guidelines instructing employees displaying flu-like, or C LVID -like symptoms to be sent home, and to contact their medical provider and self isolate. In consideration of the mutual covenants hereinafter set forth, the parties, intending to be legally bound, agree as follows: I. Term This Agreement shat€ begin on the Effective Date and continue far a period of six -months or as specified in the quotation (the "Initial Term") and automatically renewed thereafter for a six-month term within 15 days of the expiry of the then active term (collectively, the "Term"). 2. Testing Services; Dxierlty Certification and Standard of Work (a) Services: Upon the request of Company, DxTerity shall provide Cornpany with COVI0-19 Employer Testing Services in accordance with service ordering and delivery instructions. DxTerity represents and warrants to Company that it will perform all Services under this Agreement in a professional and timely manner consistent with DocuSign Envelope iD- 25DCORf 1-7EQ.A-4E7D-94CF-E839D25FA6F1 DxTerity Exhibit A SafeWorkDx Employer Testing Service Site Based Service Product Description: On Site Employer Testing For COVID-19 DxTerity Diagnostics- Inc. "DxTerity" has developed COVID-19 testing that provides employers with cost-effective; confidential access to RHA testing for their employees and contractors that may have the SARS CoV-2 virus ("SARS-COV-2 RNA Testi ng"). DxTerity is a CLIA- licensed, CAP -accredited dinicaI laboratory. DxTerity's SARS-CoV-2 test has been CLIA - validated and approved for FDA Emergency Use Authorization. The DxTerity Employer Testing Service uses a saliva collector for collection by employees from their workplace of site utilizing our SafeWorkDx'" Platform ("Services"). The platform allows the Company to place batch orders for sites to conduct testing of authorized individuals. Once the company account is established, designated representatives can conduct testing events, place orders, process shipping and view results within the SafeWrsrkdxTm Platform. The service requires the Company representative to: 1) Complete Consent Forms and populate required information in the SafeWorkDx'' Platform. 2) Schedule collection events, places orders and conduct collection events. 3) Register manifest and specimens in the platform - 4) View reports in the platform to review results and share with individuals as needed. The Company Administrator oversees the ordering and the administration of Company protocols regarding workplace safety. All test results are reported back to the Company Administrator with both group and individual reports. The - Company representative provides reports to the individual Employee/Contractor. The "Services" include: ■ Supply of saliva collection kits, specimen labels and packaging materials for shipment of saliva collection kits to DxTerity. • Company sample collection interface and online testing portal SafeWorkDx. • Training a Company Administrator, Site Representative and/or delegates to manage sample collection, shipping, safe handling, and handling of PHI, ■ SARS-CoV-2 RNA testing and reporting. Attachments for instructions to Periorm Exhibit A: �■ Quote for Services Example Consent Form Shipping of Biohazardous Materials a Responsibilities of Site Representative Patient Fact Sheet • FAQs 6 Instructions for Use of Saliva Collection Device DocL,Sign Envelope ID: 25DCOB11-7EDA4E70-94CF-5839026FA6F1 DxTerity Exhibit B SafeWorkDx Employer Testing Service From Home Product Description: Employer Testing for COVID-19 From Home DxTerity Diagnostics Inc. "DxTerity" has developed COVID-19 testing that provides employers with cost-effective, confidential access to RNA testing for their employees and contractors that may have the SARS CoV-2 virus ("SARs-CoV-2 RNA Testing"). DxTerity is a CLIA -licensed, CAP -accredited clinical laboratory. DxTerity's SARS-CoV-2 test has been CLIA - validated and approved for FDA Emergency Use Authorization. The DxTerity Employer Testing Service uses a saliva collector for collection by employees from home utilizing our SafeWorkDxTm Platform ("Services"). The platform allows the Company to place individual orders for employees or other authorized individuals to receive testing kits at their home address. Once the order is placed by the Company the individual receives account creation and login to the platform. In the platform the employee performs the following: 1] Employee/Contractor completes Consent Form and required Information in SafeWorkDx'11 Platform. 2) Employee/Contractor completes a screener for symptoms. 3] Employee/Contractor places order. 4) Employee/Contractor receives kit and registers order and specimen in platform and collects sample. 5) Employee/Contractor and Company representative returns to platform to review results. The Company must designate a Company Administrator who oversees the ordering of from home kits and the administration of Company protocols regarding workplace safety. All test results are reported back to the Company Administrator, and the individual Employee/Contractor. The "Services" include: Supply of saliva collection kits, specimen labels and packaging materials for home shipment of saliva collection kits to DxTerity ■ Individual and company online testing portal access for SafeWorkDXTM, + Training a Company Administrator, Site Representative and/or delegates to manage the process. a -SARS-CoV-2 RNA testing Orders for the From Home COVID-19 Employer Testing Service: Orders properly executed from the platform will be delivered to the individual Employee/Contractor within 2-3 days of order. Return shipment as described in the DxTerity Test Kit Instructions for Use, must be delivered to FedEx before shipment cutoff for next day delivery. DxTerity is not responsible for re -testing Employees/Contractors for non - reportable results due to the failure of an Employee/Contractor to follow the DxTerity Test Kit Instructions for Use. DxTerity will replace any orders/tests which are damaged in shipment or lost by shipper. Attachments for instruction to perform Exhibit -8: • Quote for Services Online Consent Form ■ DxTerity Test Kit Instructions For Use • Responsibilities of Site Representative ■ Patient Fact Sheet 9 Instructions for Use of Saliva Collection Device Docu5ign Envelope ID: 250001311.7EDA-4E7D-94GF-E839D26FA6F1 DxTerity Contact: Brett 5wansiger Chief Commercial Officer Office: (310) 537-7857 Email: bswansiger@dxterity.com For: Jennifer Rabies Executive Assistant to the City Manager City of Seal Beach 211 Eighth Street, Seal Beach, CA 90740 Lry b les @ sea I be ach ca .gov Phone: (562) 431-2527 Ext. 1326 COVID-19 Project Services, Materials & Support: • DxTerity Diagnostics 19500 5 Rancho Way, suite 116 Rancho Dominguez, CA 90220 Number: CVD -1000915 Created: January 12, 2021 Expires: July 12, 2021 • Qualitative detections of nucleic acid from SARS-CoV-2 in saliva • Site Representative training, software and supporting documentation ■ Biohazard shipping return containers and packaging materials with instructions and FedEx return air bills • Confidential COVID-19 reporting to Company Administrator via "From Wow testing program • Confidential COVID-19 reporting to Employee and Company Administrator via "At -Home" testing program • Results provided within 24 hours from receipt at DxTerity testing facility excluding sampies requiring retest due to sample quality or indeterminate results. Retest results reported within 49 hours. Service options List Price $ 2,500 Discount Price Oitan tY TOW One-time Account Set-up per Site/ Business Unit Account registration, software and training. Outbound shipment of Saliva collection devices, bar code scanner(s), Class 8 packaging materials for return to DxTerity and FedEx }ire -label for shipment os E I 1 Waved _ "From WorV' SARS-CoV-2 (COVID-19) Testing Forecast per client. Discounted subscript[on requires 6 -month commitment First 30 days: employee weekly testing $125 $ 50 540 $ 25,000 Month One Sub -Total $ 25,000 Each Additional 30 days: employees Ix weekly $125 $ 50 500 $ 25,000 "At -Home" SARS-CoV-2 (COV I0-19) Single Collection Kit. Includes priority fed Ex return shipping First 30 days: Estimated Single Collection Testing Services $125 n%a 5 Month One Sub-Totaf $ Each Additional 30 days. employees 1 x weekly $125 n/a S Rage 1 of 3 CONFIDENTIAL DxTerity Diagnostics Inc. 19500 5, Rancho Way, Suite 116, Rancho ❑ominquez, CA 90220 Fy tj- 2.0 ZNr-k City of Seal Beach Combining Statement of Revenues, Expenditures, and Changes in Fund Balances Nonmajor Governmental Funds For the Year Ended June 30, 2020 street Liglrtin Re' enuex: Tures S 140.163 lntergovernMental - Charges for services Use of money and propert Contributions - Total re►,enues 140.163 Expenditures: Current: General government . Pub] is safety - Community development - Public works 149,431 Debt service: Principal - Interest and Escal charges - Total expenditures 199,431 - Revenues ewer (under) expenditures (59,268) Lather Financing Sources (lases): Transfers in 59,268 Transfers out - Total other financing sources (uses) 59,269 Net cit angc ire Fu nd balances Fund Balance: Beginning of Year End of Year 107